Finance

Lists
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
25,86 $
+2,13%
(+0,54) 1D
21 там., 15:59:45 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
25,76 $
High
26,75 $
Low
25,69 $
Mkt. cap
2,55 млрд
Avg. vol.
1,92 млн
Volume
1,77 млн
52-wk high
39,89 $
52-wk low
18,29 $
EPS
-5,84 $
Beta
0,35
Shares outstanding
98,59 млн
No. of employees
1 мың
Open
25,76 $
High
26,75 $
Low
25,69 $
Mkt. cap
2,55 млрд
Avg. vol.
1,92 млн
Volume
1,77 млн
52-wk high
39,89 $
52-wk low
18,29 $
EPS
-5,84 $
Beta
0,35
Shares outstanding
98,59 млн
No. of employees
1 мың
News stories
From web sources and news partners
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 мың
Founded2010
HeadquartersNovato, Калифорния, Америка Құрама Штаттары
Sector-
Websiteultragenyx.com
Analyst ratings
Based on 18 analysts giving stock ratings to RARE in the past 3 months
Strong buy
Buy
16
Hold
2
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for RARE in the last 3 months.
Highest
Current 25,86 $
103,00 $ (+298,30%)
Average
54,06 $ (+109,05%)
Lowest
28,00 $ (+8,28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Jefferies
Buy
Maintained
77,00 $
+197,8%
08/21/2026
Maxwell Skor
Morgan Stanley
Buy
Reiterated
74,00 $
+186,2%
08/21/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
48,00 $
+85,6%
08/20/2026
Unknown Analyst
Wedbush
Hold
Maintained
30,00 $
+16%
08/20/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
08/19/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
103,00 $
+298,3%
08/19/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
28,00 $
+8,3%
08/20/2026
Whitney Ijem
Canaccord Genuity
Buy
Reiterated
83,00 $
+221%
08/20/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
46,00 $
+77,9%
08/20/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
50,00 $
+93,3%
08/21/2026
Yigal Nochomovitz
Citi
Buy
Maintained
58,00 $
+124,3%
08/20/2026
Sami Corwin
William Blair
Buy
Initiated
-
-
08/20/2026
Yaron Werber
TD Cowen
Buy
Maintained
49,00 $
+89,5%
08/19/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
68,00 $
+163%
08/17/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
33,00 $
+27,6%
08/10/2026
Laura Chico
Wedbush
Hold
Maintained
30,00 $
+16%
08/05/2026
Luca Issi
RBC Capital
Buy
Maintained
40,00 $
+54,7%
08/05/2026
Eliana Merle
Barclays
Buy
Maintained
43,00 $
+66,3%
08/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
35,00 $
+35,3%
08/03/2026
Jack Allen
Robert W. Baird
Buy
Maintained
40,00 $
+54,7%
02/13/2026
Joon Lee
Truist Financial
Buy
Maintained
76,00 $
+193,9%
02/13/2026
Last report
2026 ж. 04 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,90 $ / -1,00 $
+9,74%beat
Revenue / Est. (USD)
214,00 млн / 183,08 млн
+16,89%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
159,93 млн
207,28 млн
136,00 млн
214,00 млн
Cost of goods sold
244,20 млн
232,62 млн
189,00 млн
201,00 млн
Cost of revenue
244,20 млн
232,62 млн
189,00 млн
201,00 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
86,62 млн
87,94 млн
86,00 млн
88,00 млн
Operating expense
86,62 млн
87,94 млн
86,00 млн
88,00 млн
Total operating expenses
330,82 млн
320,56 млн
275,00 млн
289,00 млн
Operating income
-170,89 млн
-113,28 млн
-139,00 млн
-75,00 млн
Other non operating income
-1,04 млн
-934,00 м.
-
1,00 млн
EBT including unusual items
-179,54 млн
-127,69 млн
-184,00 млн
-91,00 млн
EBT excluding unusual items
-180,22 млн
-127,17 млн
-154,00 млн
-91,00 млн
Income tax expense
873,00 м.
870,00 м.
1,00 млн
1,00 млн
Effective tax rate
-0,49%
-0,68%
-0,54%
-1,10%
Other operating expenses
-
-
-
-
Net income
-180,41 млн
-128,56 млн
-185,00 млн
-92,00 млн
Net profit margin
-112,81%
-62,02%
-136,03%
-42,99%
Earnings per share
-1,81
-1,29
-1,54
-0,90
Interest and investment income
5,86 млн
6,51 млн
6,00 млн
5,00 млн
Interest expense
-14,15 млн
-19,47 млн
-21,00 млн
-22,00 млн
Net interest expenses
-8,28 млн
-12,96 млн
-15,00 млн
-17,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-162,28 млн
-104,50 млн
-131,00 млн
-67,00 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары